Treatment escalation options for patients with type 2 diabetes after failure of exenatide twice daily or glimepiride added to metformin: results from the prospective European Exenatide (EUREXA) study

Publisher： John Wiley & Sons Inc

E-ISSN： 1463-1326|17|7|689-698

ISSN： 1462-8902

Source： DIABETES OBESITY & METABOLISM (ELECTRONIC), Vol.17, Iss.7, 2015-07, pp. : 689-698

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Treatment satisfaction with ITCA 650, a novel drug‐device delivering continuous exenatide, versus twice‐daily injections of exenatide in type 2 diabetics using metformin

By  

DIABETES OBESITY & METABOLISM (ELECTRONIC), Vol. 20, Iss. 3, 2018-03 ,pp. : 638-645

John Wiley & Sons Inc

Access to resources Recommend Favorite

The cost-effectiveness of exenatide once weekly compared with exenatide twice daily and insulin glargine for the treatment of patients with type two diabetes and body mass index ≥30 kg/m 2 in Spain

By Fonseca Tiago  

Journal of Medical Economics, Vol. 16, Iss. 7, 2013-07 ,pp. : 926-938

Informa Healthcare

Access to resources Recommend Favorite

Exenatide BID Observational Study (ExOS): results for primary and secondary endpoints of a prospective research study to evaluate the clinical effectiveness of exenatide BID use in patients with type 2 diabetes in a real-world setting

By Bergenstal Richard M.   Garrison Louis P.   Miller Lesley-Ann   Hou Likun   Blickensderfer Amy   Zagar Anthony   Stanley Shelley   Bhargava Anuj   Wade Rolin   Herman William H.  

Current Medical Research and Opinion, Vol. 27, Iss. 12, 2011-12 ,pp. : 2335-2342

Informa Healthcare

Access to resources Recommend Favorite

Effects of exenatide twice daily, exenatide once weekly or insulin in patients with type 2 diabetes and baseline HbA1c ≥10.0%: Two pooled analyses including 20 randomised controlled trials

By  

INTERNATIONAL JOURNAL OF CLINICAL PRACTICE (ELECTRONIC), Vol. 71, Iss. 12, 2017-12 ,pp. : n/a-n/a

John Wiley & Sons Inc

Access to resources Recommend Favorite

Exenatide bid observational study (ExOS): baseline population characteristics of a prospective research study to evaluate the clinical effectiveness of exenatide bid use in patients with type 2 diabetes in a real-world setting

By Bergenstal Richard M.   Garrison Louis P.   Wintle Matthew   Blickensderfer Amy   Wade Rolin   Hou Likun   Miller Lesley-Ann   Scism-Bacon Jamie   Zagar Anthony   Misurski Derek   Herman William H.  

Current Medical Research and Opinion, Vol. 27, Iss. 3, 2011-03 ,pp. : 531-540

Informa Healthcare

Access to resources Recommend Favorite